# Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT02791919** · PHASE1 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- CNS 2a
- CNS 2b
- CNS 2c
- CNS1
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Childhood Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cytarabine
- **BIOLOGICAL:** Filgrastim
- **DRUG:** Fludarabine Phosphate
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** WEE1 Inhibitor AZD1775

## Key facts

- **NCT ID:** NCT02791919
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-05-25
- **Primary completion:** 2019-05-31
- **Final completion:** 2019-05-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Other - Protocol moved to Disapproved
- **Last updated:** 2017-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02791919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02791919, "Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02791919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*